Journal of Hematology - Supplements - Haematologica

More documents

Recommendations

Info

haematologica IL TRAPIANTO DI CELLULE STAMINALI EMATOPOIETICHE NELLA PATOLOGIA PEDIATRICA ONCOEMATOLOGICA E AUTOIMMUNE ore 9 VENERDI’ 24 NOVEMBRE APERTURA DEL CONGRESSO E. Arbustini Direttore Scientifico IRCCS Burlo Garofolo, Trieste 1° SESSIONE: TRAPIANTO ALLOGENICO Moderatore F. Locatelli (Pavia) ore 9.30 Indicazioni in ematologia P. Tamaro (Trieste) ore 9.50 Il trapianto nella LLA in prima remissione C. Uderzo (Monza) ore 10.30 Trapianto non mieloablativo in pediatria R. Miniero (Torino) ore 10.50 Coffee break IRCCS BURLO GAROFOLO, TRIESTE 24-25 NOVEMBRE 2000, MUSEO REVOLTELLA 3° SESSIONE: TERAPIA DI SUPPORTO Moderatore P. Tamaro (Trieste) Medici ed infermieri. Opinioni a confronto su: ore 16.00 Profilassi e terapia delle infezioni nel trapiantato E. Gombach (Trieste), G.A. Zanazzo (Trieste) ore 16.30 Diagnostica virologica P. D’Agaro (Trieste) P. Grossi (Pavia) ore 17.00 Nutrizione parenterale e gestione del CVC M. Candusso (Cosenza) R. Guerrato (Trieste) ore 17.30 Strategie trasfusionali G. De Silvestro (Padova) S. Parco (Trieste) Discussione 2000 vol. 85 upplement o no. 11 ONTENTS ndexed by Current ntents/Life iences and in Faxon inder and Faxon XPRESS, so available n diskette with abstracts) 1 2° SESSIONE: IL PROBLEMA DEI DONATORI Moderatore R. Miniero (Torino) ore 11.20 Caratteristiche biologiche delle cellule staminali cordonali V. Rosti (Pavia) ore 11.40 Esperienze cliniche in pediatria F. Locatelli (Pavia) ore 12.00 Il trapianto da donatore volontario G. Dini (Genova) ore 12.20. Il trapianto aploidentico M. Andolina (Trieste) ore 12.40 Il trapianto aploidentico nelle immunodeficienze F. Porta (Brescia) Pranzo ore 14.30 TAVOLA ROTONDA Consensus sulla terapia della LLA in seconda remissione F. Locatelli, G. Dini, C. Uderzo, G. Basso, P. Tamaro, M. Andolina ore 15.45 Coffee break SABATO 25 NOVEMBRE 4° SESSIONE: TRAPIANTO AUTOLOGO Moderatore A. Ventura (Trieste) ore 9.00 Indicazioni nei tumori solidi S. Dall’Orso (Genova) ore 9.30 Indicazioni nelle malattie autoimmuni A. Marmont (Genova) ore 10.00 Trapianto non mieloablativo: l’esperienza di Trieste M. Rabusin (Trieste) ore 10.20 Deplezione funzionale dei linfociti G. Presani (Trieste) ore 10.30 Autotrapianto vs. trattamenti alternativi in reumatologia pediatrica L. Lepore (Trieste) ore 11.00 Coffee break ore 11.30 Trapianto si, trapianto no nelle malattie autoimmuni: casi clinici commentati dall’esperto A. Marmont (Genova), A. Martini (Pavia), F. Zulian (Padova), F. Falcini (Firenze), R. Cimaz (Milano), M. Gattorno (Genova) ore 13.30 Chiusura del congresso
haematologica Journal of Hematology volume 85 – supplement to number 11 – November 2000 HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC ONCOLOGIC-HEMATOLOGIC AND AUTOIMMUNE DISEASES Trieste, November 24-25, 2000, IRCCS “Burlo Garofolo” The history of pediatric bone marrow transplantation began in 1984. From then to December 1999 20 teams performed more than 2800 autologous and allogeneic transplants. The members of the Italian Pediatric Association for Haematology and Oncology (AIEOP) were the first in Italy to organize a Co-operative Group. In 1984 both autologous and allogeneic transplants were performed in leukemia and solid tumors; in 1986 we performed the first haploidentical bone marrow transplantation (BMT), in 1989 the first matched unrelated donor (MUD) BMT, in 1994 the first cord blood bone marrow transplantation. In 1994 even autoimmune diseases became an indication for autologous bone marrow transplantation. This huge activity led to several cooperative studies, publications and meetings. This meeting will try to give an overview of the outstanding results of the Erice meetings. We will focus on the questions that need an answer in year 2000: • indications for BMT, focusing on the new ones and on the ones that to day seem obsolete • reduction of toxicity of conditioning regimens; • stem cells sources others than HLA identical sibling: MUD, cord blood, haploidentical donors • consensus on the most important indication for BMT: acute lymphoblastic leukemia in second complete remission; • autoimmune diseases: immunoablation with or without stem cell rescue; • supportive therapy: in cooperation with the nurses we will try to design common protocols of prevention and treatment of infections, of parenteral nutrition and transfusion strategy. The spectrum of diseases curable by hematopoietic stem cell transplantation is getting larger, although the decision whether to offer a transplant or alternative therapy can be difficult because of so many factors which can affect with short and long-term outcome and quality of life of the patients. The AIEOP Group, by accumulating information from multicenter studies and the national Registry, is now able define the priorities for future recommendations in the care of patients with hematologic malignancies or disorders. Finally, new research trends need to be defined, not only in the clinical setting but also in immunobiology and all other fields of interest, in order to improve the management and results of the BMT procedures. the editors M. Andolina, G. Dini, C. Uderzo haematologica vol. 85(10):October 2000
Page 1: Haematologica established in 1920 e
Page 5 and 6: 3 Table 1. Indications for allogene
Page 7 and 8: 5 ease-free survival for childhood
Page 9 and 10: 7 Allogeneic bone marrow transplant
Page 11 and 12: haematologica 2000; 85(supplement t
Page 13 and 14: 11 achieved. However the relapse ra
Page 15 and 16: 13 ease. This observation is confir
Page 17 and 18: 15 plant failure. The role of DLI i
Page 19 and 20: 17 non-myeloablative regimen. Blood
Page 21 and 22: apheretic products obtained after m
Page 23 and 24: 21 Kinetics of activation of CFC in
Page 25 and 26: 23 according to the flow cytometric
Page 27 and 28: 25 mal cell activators and inhibito
Page 29 and 30: 27 reduced responsiveness to alloge
Page 31 and 32: 29 15 from activated cord versus ad
Page 33 and 34: 31 reported on the initial experien
Page 35 and 36: 33 Table 5. Timing and causes of tr
Page 37 and 38: 35 of children with storage disorde
Page 41 and 42: 39 parents wishes (the patient was
Page 45 and 46: 43 washing the cell suspension and
Page 47 and 48: 45 tive selection is usually around
Page 51 and 52: 49 chemotherapy blocks has been adm
Page 53 and 54:
51 Recently some clinical studies h
Page 55 and 56:
53 lymphoblastic leukaemia in Italy
Page 57 and 58:
55 Table 1. Summary of clinical dat
Page 59 and 60:
57 HLA-restricted cytomegalovirus (
Page 61 and 62:
59 that short-term artificial nutri
Page 63 and 64:
61 chain triglycerides in total par
Page 65 and 66:
63 1 2 3 4 5 Figure 1. Answers to t
Page 67 and 68:
65 References 1. Clarke DE, Raffin
Page 69 and 70:
67 therapy including colony-stimula
Page 71 and 72:
69 platin-thiotepa-etoposide is 34%
Page 73 and 74:
haematologica 2000; 85(supplement t
Page 75 and 76:
73 Multiple sclerosis MS is charact
Page 77 and 78:
75 Special Issues Conditioning The
Page 79 and 80:
77 ticated studies with gene-marked
Page 81 and 82:
79 treatment of poor risk systemic
Page 83 and 84:
Page 85 and 86:
83 Table 1. Rheumatologic disorders
Page 87 and 88:
85 ly in terms of steroid-sparing a
Page 89 and 90:
87 the same buffer was added to all
Page 91 and 92:
Page 93 and 94:
91 patients, 10 with a systemic for
Page 95 and 96:
I index of authors Albertini A 41 A
show all

Journal of Hematology - Supplements - Haematologica

Create successful ePaper yourself

Delete template?

Save as template?